Selected research
Market Outlook & Growth Opportunities
Global Radiopharmaceuticals for Diagnosis Market Outlook and Growth Opportunities 2026
Market perspective
The global Radiopharmaceuticals for Diagnosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Radiopharmaceuticals for Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Radiopharmaceuticals for Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Radiopharmaceuticals for Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Radiopharmaceuticals for Diagnosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Radiopharmaceuticals for Diagnosis market include Atom High-tech Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Tianjin Said Biopharmaceutical Co., Ltd., Shenzhen Larven Bioengineering Technology Co., Ltd., Shanghai Atom Kexing Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Ningbo Jun'an Pharmaceutical Technology Co., Ltd., Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. and Guangdong Xi'ai Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Radiopharmaceuticals for Diagnosis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Radiopharmaceuticals for Diagnosis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Radiopharmaceuticals for Diagnosis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceuticals for Diagnosis market size, projected growth trends, production technologies, key applications, and end-use industries.
Radiopharmaceuticals for Diagnosis Segment by Company
Atom High-tech Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Tianjin Said Biopharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
RadioMedix, Inc.
PDRadiopharma Inc.
Lantheus
Jubilant Radiopharma
GE Healthcare Ltd
DOE IP
Radiopharmaceuticals for Diagnosis Segment by Type
Strontium [89Sr] Chloride
Sodium Iodide [131I]
Iodine [125I] Sealed Seed Source
Technetium [99mTc] Pentetate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Dithiodithiocarbamate
Other
Radiopharmaceuticals for Diagnosis Segment by Application
Hospital
Clinic
Other
Radiopharmaceuticals for Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Radiopharmaceuticals for Diagnosis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Radiopharmaceuticals for Diagnosis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Radiopharmaceuticals for Diagnosis significant trends, drivers, influence factors in global and regions.
6. To analyze Radiopharmaceuticals for Diagnosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radiopharmaceuticals for Diagnosis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceuticals for Diagnosis industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals for Diagnosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Radiopharmaceuticals for Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Radiopharmaceuticals for Diagnosis in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Strontium [89Sr] Chloride
- Sodium Iodide [131I]
- Iodine [125I] Sealed Seed Source
- Technetium [99mTc] Pentetate
- Technetium [99mTc] Polymerized Albumin
- Technetium [99mTc] Dithiodithiocarbamate
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Atom High-tech Co., Ltd.
- Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
- Tianjin Said Biopharmaceutical Co., Ltd.
- Shenzhen Larven Bioengineering Technology Co., Ltd.
- Shanghai Atom Kexing Pharmaceutical Co., Ltd.
- Shanghai Xinke Pharmaceutical Co., Ltd.
- Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
- Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
- Guangdong Xi'ai Pharmaceutical Co., Ltd.
- Chengdu Zhonghe Gaotong Isotope Co., Ltd.
- Chengdu Yunke Pharmaceutical Co., Ltd.
- Chengdu Xinke Pharmaceutical Co., Ltd.
- Beijing Zhibo High-tech Biotechnology Co., Ltd.
- RadioMedix, Inc.
- PDRadiopharma Inc.
- Lantheus
- Jubilant Radiopharma
- GE Healthcare Ltd
- DOE IP
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 1.2.2 Global Radiopharmaceuticals for Diagnosis Sales Volume (2021-2032)
- 1.2.3 Global Radiopharmaceuticals for Diagnosis Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Radiopharmaceuticals for Diagnosis Market Dynamics
- 2.1 Radiopharmaceuticals for Diagnosis Industry Trends
- 2.2 Radiopharmaceuticals for Diagnosis Industry Drivers
- 2.3 Radiopharmaceuticals for Diagnosis Industry Opportunities and Challenges
- 2.4 Radiopharmaceuticals for Diagnosis Industry Restraints
3 Radiopharmaceuticals for Diagnosis Market by Company
- 3.1 Global Radiopharmaceuticals for Diagnosis Company Revenue Ranking in 2025
- 3.2 Global Radiopharmaceuticals for Diagnosis Revenue by Company (2021-2026)
- 3.3 Global Radiopharmaceuticals for Diagnosis Sales Volume by Company (2021-2026)
- 3.4 Global Radiopharmaceuticals for Diagnosis Average Price by Company (2021-2026)
- 3.5 Global Radiopharmaceuticals for Diagnosis Company Ranking (2024-2026)
- 3.6 Global Radiopharmaceuticals for Diagnosis Company Manufacturing Base and Headquarters
- 3.7 Global Radiopharmaceuticals for Diagnosis Company Product Type and Application
- 3.8 Global Radiopharmaceuticals for Diagnosis Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Radiopharmaceuticals for Diagnosis Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Radiopharmaceuticals for Diagnosis Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceuticals for Diagnosis Market by Type
- 4.1 Radiopharmaceuticals for Diagnosis Type Introduction
- 4.1.1 Strontium [89Sr] Chloride
- 4.1.2 Sodium Iodide [131I]
- 4.1.3 Iodine [125I] Sealed Seed Source
- 4.1.4 Technetium [99mTc] Pentetate
- 4.1.5 Technetium [99mTc] Polymerized Albumin
- 4.1.6 Technetium [99mTc] Dithiodithiocarbamate
- 4.1.7 Other
- 4.2 Global Radiopharmaceuticals for Diagnosis Sales Volume by Type
- 4.2.1 Global Radiopharmaceuticals for Diagnosis Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Radiopharmaceuticals for Diagnosis Sales Volume by Type (2021-2032)
- 4.2.3 Global Radiopharmaceuticals for Diagnosis Sales Volume Share by Type (2021-2032)
- 4.3 Global Radiopharmaceuticals for Diagnosis Sales Value by Type
- 4.3.1 Global Radiopharmaceuticals for Diagnosis Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Radiopharmaceuticals for Diagnosis Sales Value by Type (2021-2032)
- 4.3.3 Global Radiopharmaceuticals for Diagnosis Sales Value Share by Type (2021-2032)
5 Radiopharmaceuticals for Diagnosis Market by Application
- 5.1 Radiopharmaceuticals for Diagnosis Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Radiopharmaceuticals for Diagnosis Sales Volume by Application
- 5.2.1 Global Radiopharmaceuticals for Diagnosis Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Radiopharmaceuticals for Diagnosis Sales Volume by Application (2021-2032)
- 5.2.3 Global Radiopharmaceuticals for Diagnosis Sales Volume Share by Application (2021-2032)
- 5.3 Global Radiopharmaceuticals for Diagnosis Sales Value by Application
- 5.3.1 Global Radiopharmaceuticals for Diagnosis Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Radiopharmaceuticals for Diagnosis Sales Value by Application (2021-2032)
- 5.3.3 Global Radiopharmaceuticals for Diagnosis Sales Value Share by Application (2021-2032)
6 Radiopharmaceuticals for Diagnosis Regional Sales and Value Analysis
- 6.1 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Radiopharmaceuticals for Diagnosis Sales by Region (2021-2032)
- 6.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2021-2026
- 6.2.2 Global Radiopharmaceuticals for Diagnosis Sales by Region (2027-2032)
- 6.3 Global Radiopharmaceuticals for Diagnosis Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Radiopharmaceuticals for Diagnosis Sales Value by Region (2021-2032)
- 6.4.1 Global Radiopharmaceuticals for Diagnosis Sales Value by Region: 2021-2026
- 6.4.2 Global Radiopharmaceuticals for Diagnosis Sales Value by Region (2027-2032)
- 6.5 Global Radiopharmaceuticals for Diagnosis Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 6.6.2 North America Radiopharmaceuticals for Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 6.7.2 Europe Radiopharmaceuticals for Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Radiopharmaceuticals for Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 6.9.2 South America Radiopharmaceuticals for Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Radiopharmaceuticals for Diagnosis Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Radiopharmaceuticals for Diagnosis Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceuticals for Diagnosis Country-level Sales and Value Analysis
- 7.1 Global Radiopharmaceuticals for Diagnosis Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Radiopharmaceuticals for Diagnosis Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Radiopharmaceuticals for Diagnosis Sales by Country (2021-2032)
- 7.3.1 Global Radiopharmaceuticals for Diagnosis Sales by Country (2021-2026)
- 7.3.2 Global Radiopharmaceuticals for Diagnosis Sales by Country (2027-2032)
- 7.4 Global Radiopharmaceuticals for Diagnosis Sales Value by Country (2021-2032)
- 7.4.1 Global Radiopharmaceuticals for Diagnosis Sales Value by Country (2021-2026)
- 7.4.2 Global Radiopharmaceuticals for Diagnosis Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.9.2 France Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.16.2 China Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.19.2 India Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Radiopharmaceuticals for Diagnosis Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Radiopharmaceuticals for Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Radiopharmaceuticals for Diagnosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Atom High-tech Co., Ltd.
- 8.1.1 Atom High-tech Co., Ltd. Company Information
- 8.1.2 Atom High-tech Co., Ltd. Business Overview
- 8.1.3 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.1.5 Atom High-tech Co., Ltd. Recent Developments
- 8.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
- 8.2.1 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Company Information
- 8.2.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Business Overview
- 8.2.3 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.2.5 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Recent Developments
- 8.3 Tianjin Said Biopharmaceutical Co., Ltd.
- 8.3.1 Tianjin Said Biopharmaceutical Co., Ltd. Company Information
- 8.3.2 Tianjin Said Biopharmaceutical Co., Ltd. Business Overview
- 8.3.3 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.3.5 Tianjin Said Biopharmaceutical Co., Ltd. Recent Developments
- 8.4 Shenzhen Larven Bioengineering Technology Co., Ltd.
- 8.4.1 Shenzhen Larven Bioengineering Technology Co., Ltd. Company Information
- 8.4.2 Shenzhen Larven Bioengineering Technology Co., Ltd. Business Overview
- 8.4.3 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.4.5 Shenzhen Larven Bioengineering Technology Co., Ltd. Recent Developments
- 8.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd.
- 8.5.1 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Company Information
- 8.5.2 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Business Overview
- 8.5.3 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.5.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Recent Developments
- 8.6 Shanghai Xinke Pharmaceutical Co., Ltd.
- 8.6.1 Shanghai Xinke Pharmaceutical Co., Ltd. Company Information
- 8.6.2 Shanghai Xinke Pharmaceutical Co., Ltd. Business Overview
- 8.6.3 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.6.5 Shanghai Xinke Pharmaceutical Co., Ltd. Recent Developments
- 8.7 Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
- 8.7.1 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Company Information
- 8.7.2 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Business Overview
- 8.7.3 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.7.5 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Recent Developments
- 8.8 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
- 8.8.1 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Company Information
- 8.8.2 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Business Overview
- 8.8.3 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.8.5 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Recent Developments
- 8.9 Guangdong Xi'ai Pharmaceutical Co., Ltd.
- 8.9.1 Guangdong Xi'ai Pharmaceutical Co., Ltd. Company Information
- 8.9.2 Guangdong Xi'ai Pharmaceutical Co., Ltd. Business Overview
- 8.9.3 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.9.5 Guangdong Xi'ai Pharmaceutical Co., Ltd. Recent Developments
- 8.10 Chengdu Zhonghe Gaotong Isotope Co., Ltd.
- 8.10.1 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Company Information
- 8.10.2 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Business Overview
- 8.10.3 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.10.5 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Recent Developments
- 8.11 Chengdu Yunke Pharmaceutical Co., Ltd.
- 8.11.1 Chengdu Yunke Pharmaceutical Co., Ltd. Company Information
- 8.11.2 Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
- 8.11.3 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.11.5 Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
- 8.12 Chengdu Xinke Pharmaceutical Co., Ltd.
- 8.12.1 Chengdu Xinke Pharmaceutical Co., Ltd. Company Information
- 8.12.2 Chengdu Xinke Pharmaceutical Co., Ltd. Business Overview
- 8.12.3 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.12.5 Chengdu Xinke Pharmaceutical Co., Ltd. Recent Developments
- 8.13 Beijing Zhibo High-tech Biotechnology Co., Ltd.
- 8.13.1 Beijing Zhibo High-tech Biotechnology Co., Ltd. Company Information
- 8.13.2 Beijing Zhibo High-tech Biotechnology Co., Ltd. Business Overview
- 8.13.3 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.13.5 Beijing Zhibo High-tech Biotechnology Co., Ltd. Recent Developments
- 8.14 RadioMedix, Inc.
- 8.14.1 RadioMedix, Inc. Company Information
- 8.14.2 RadioMedix, Inc. Business Overview
- 8.14.3 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.14.4 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.14.5 RadioMedix, Inc. Recent Developments
- 8.15 PDRadiopharma Inc.
- 8.15.1 PDRadiopharma Inc. Company Information
- 8.15.2 PDRadiopharma Inc. Business Overview
- 8.15.3 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.15.4 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.15.5 PDRadiopharma Inc. Recent Developments
- 8.16 Lantheus
- 8.16.1 Lantheus Company Information
- 8.16.2 Lantheus Business Overview
- 8.16.3 Lantheus Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.16.4 Lantheus Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.16.5 Lantheus Recent Developments
- 8.17 Jubilant Radiopharma
- 8.17.1 Jubilant Radiopharma Company Information
- 8.17.2 Jubilant Radiopharma Business Overview
- 8.17.3 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.17.4 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.17.5 Jubilant Radiopharma Recent Developments
- 8.18 GE Healthcare Ltd
- 8.18.1 GE Healthcare Ltd Company Information
- 8.18.2 GE Healthcare Ltd Business Overview
- 8.18.3 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.18.4 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.18.5 GE Healthcare Ltd Recent Developments
- 8.19 DOE IP
- 8.19.1 DOE IP Company Information
- 8.19.2 DOE IP Business Overview
- 8.19.3 DOE IP Radiopharmaceuticals for Diagnosis Sales, Value and Gross Margin (2021-2026)
- 8.19.4 DOE IP Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.19.5 DOE IP Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Radiopharmaceuticals for Diagnosis Value Chain Analysis
- 9.1.1 Radiopharmaceuticals for Diagnosis Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Radiopharmaceuticals for Diagnosis Sales Mode & Process
- 9.2 Radiopharmaceuticals for Diagnosis Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Radiopharmaceuticals for Diagnosis Distributors
- 9.2.3 Radiopharmaceuticals for Diagnosis Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst